January 11, 2010

Incidence and Predictive Factors for Infectious Disease after Rituximab Therapy in Kidney-Transplant Patients


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

Rituximab is being used in renal transplantation to treat donor-specific antibodies pre-transplant of acute humoral rejection post-transplant. This is a single-center retrospective study of transplant patients who received rituximab for a variety of reasons. Compared to a control group, there was an increase rate of death from infection, including unusual infections.

Renal Transplantation